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Abstract 
 
Background: Dissemination of breast cancers to the brain is associated with poor patient 
outcome and limited therapeutic options. In this study we sought to identify novel regulators 
of brain metastasis by profiling mouse mammary carcinoma cells spontaneously 
metastasising from the primary tumour in an immunocompetent syngeneic host. 
 
Methods:  4T1 mouse mammary carcinoma sublines derived from primary tumours and 
spontaneous brain and lung metastases in BALB/c mice, were subject to genome-wide 
expression profiling. Two differentially expressed genes, Id2 and Aldh3a1, were validated in 
in vivo models using mouse and human cancer cell lines. Clinical relevance was investigated 
in datasets of breast cancer patients with regards to distant metastasis free survival and brain 
metastasis relapse free survival. The role of BMP7 in regulating Id2 expression and promoting 
cell survival was investigated in 2D and 3D in vitro assays. 
 
Results: In the spontaneous metastasis model, expression of Id2 and Aldh3a1 is significantly 
higher in 4T1 brain-derived sublines compared to sublines from lung metastases or primary 
tumour. Downregulation of expression impairs the ability of cells to colonise the brain 
parenchyma whereas ectopic expression in 4T1 and human MDA-MB-231 cells promotes 
dissemination to the brain following intracardiac inoculation but has no impact on the efficiency 
of lung colonisation. Both genes are highly expressed in ER-negative breast cancers and 
within this poor prognosis subgroup, increased expression correlates with reduced distant 
metastasis-free survival. ID2 expression also associates with reduced brain metastasis 
relapse-free survival. Mechanistically, BMP7, which is present at significantly higher levels in 
brain tissue compared to the lungs, upregulates ID2 expression and after BMP7 withdrawal, 
this elevated expression is retained. Finally, we demonstrate that either ectopic expression of 
ID2 or BMP7-induced ID2 expression protects tumour cells from anoikis. 
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Conclusions: This study identifies ID2 as a key regulator of breast cancer metastasis to the 
brain. Our data support a model in which breast cancer cells that have disseminated to the 
brain upregulate ID2 expression in response to astrocyte-secreted BMP7 and this serves to 
support metastatic expansion. Moreover, elevated ID2 expression identifies breast cancer 
patients at increased risk of developing metastatic relapse in the brain.  
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Introduction 
Metastasis of breast cancer to the brain represents an area of high unmet medical need. 15-
30% of patients with metastatic breast cancer will develop brain metastases and brain is the 
first site of metastasis in 7-16% of metastatic patients [1]. Survival upon a brain metastasis 
diagnosis is 4 months to 2 years, with worse prognosis for patients with triple negative (TN) 
breast cancer or multiple brain lesions and better prognosis for those with ER+ or HER2+ 
disease or a single brain metastasis [2, 3]. The incidence of brain metastasis for breast and 
other cancers has been increasing, likely due to improved imaging and other diagnostic 
technologies and more effective systemic and targeted therapies which prolong patient 
survival by controlling extracranial disease. However, agents that control systemic disease 
often have poor brain penetrance resulting in failure to control disease progression [4, 5].  
 Over the past decade there has been significant progress in understanding the 
mechanisms underpinning brain metastasis, including the identification of key molecular 
events required for successful tumour cell transmigration across the blood brain barrier and 
for avoiding apoptosis once the cells have reached the brain parenchyma [1, 5-8]. However, 
these studies have relied heavily on directly inoculating tumour cells into the left ventricle of 
the heart and on the use of human cell lines in immunocompromised mice. Such a scenario 
fails to recapitulate the clinical setting where low numbers of circulating tumour cells will 
encounter different organs and have to avoid immune attack [7]. To better mimic human 
disease we used a model of spontaneous metastasis of 4T1 mouse mammary carcinoma cells 
in syngeneic, immunocompetent BALB/c mice. We have profiled 4T1 sublines derived from 
primary tumours and from tumour cells that had disseminated to the lungs and brain and 
performed in vivo validation experiments and assessment of clinical datasets. Using this 
approach, we identified a role for ID2 and ALDH3A1 in promoting metastatic colonisation and 
for ID2 in promoting brain-specific metastasis. 
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Methods 
Cells and reagents 
4T1 cells were obtained from ATCC, tagged with luciferase using lentiviral particles expressing 
Firefly luciferase (Amsbio) and grown in DMEM supplemented with 10% FBS. MDA-MB-231-
Luc cells were obtained from Sibtech and grown in DMEM supplemented with 10% FBS. 
Where indicated, 4T1-Luc cells were transduced with lentiviral particles expressing H2B-
mRFP as previously described [9] and RFP+ cells enriched by FACSorting. Cells were STR 
tested regularly using StemElite ID system (Promega). Both cell types were routinely tested 
for mycoplasma and used within 10 passages after resuscitation. Mouse astrocytes were 
purchased from ScienCell and maintained in astrocyte basal medium supplemented with FBS 
and astrocyte growth supplement. Recombinant human TGFb-1 and BMP7 were purchased 
from R&D systems. Details of shRNA lentiviruses, full length ORF clone expression systems, 
RT-qPCR reagents and antibodies used in this study are provided in Additional file 1; Tables 
S1 - S4.  
 For shRNA knockdown of Id2 or Aldh3a1, 5 x 104 4T1-Luc cells were transduced with 
lentiviral particles (Sigma; Mission transduction particles) at an MOI of 2. 24 h post 
transduction, medium was replaced with fresh medium containing 10% FBS. Stably 
transduced cells were selected in 2.5 µg/mL puromycin for 2 passages.   
 For ectopic expression of Id2 or Aldh3a1, 8 µg of bicistronic mammalian expression 
vector pReceiver-Lv166 mCherry vector with or without full length ORF for mouse Id2 (EX-
Mm03201-Lv166) or Aldh3a1 (EX-Mm28326-Lv166-GS) purified plasmid, 4 µg of packaging 
plasmid psPAX2, and 1.5 µg envelope plasmid pMD2.G were co-transfected into the 
HEK293T cells using OptiMEM and Lipofectamine 2000. 48 h post transfections, virus 
containing medium was collected and used to directly infect 4T1-Luc or MDA-MB-231-Luc 
cells. 72 h post infection, cells were FACS sorted to enrich for mCherry-positive cells. 
 
In vivo experiments 
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All animals were monitored on a daily basis by staff from the ICR Biological Service Unit for 
signs of ill health.  
 To isolate tumour cells disseminated to metastatic sites for gene expression profiling, 
1 x 104 4T1-Luc cells in 50 µL PBS were inoculated subcutaneously into 6-8 week female 
BALB/c mice. Once primary tumours reached maximum (mean diameter ≥15 mm) allowable 
size, the mice were sacrificed. Primary tumours, lungs and brains were harvested at necropsy. 
Primary tumours were individually cut into small pieces, homogenized using a McIlwain Tissue 
Chopper (Campden Instruments), digested in L-15 medium containing 3 mg/mL collagenase 
type I at 37°C for 1 hour, followed by digestion with 0.025 mg/mL DNase1 at 37°C for 5 min. 
After erythrocyte lysis using Red Blood Cell Lysing Buffer (Sigma), the cell suspension was 
plated into a 10 cm dish in 10 mL DMEM plus 10% FBS. Individual lungs and brains were 
placed in 1 mL PBS on a 40 µm sieve in a 6 cm plate, mechanically dissociated by pushing 
through the sieve and cultured in 2 mL DMEM plus 10% FBS in 6 cm dishes. When primary 
tumour-, brain- and lung-derived 4T1 colonies were visible, cells were passaged 3-4 times 
before RNA was extracted from individual sublines for gene expression profiling. 
 For experimental metastasis assays, 6-8 week female BALB/c or NOD scid gamma 
(NSG) mice were inoculated with 4T1-Luc or MDA-MB-231 cells. For intracranial inoculations 
mice were anaesthetised with isoflurane and injected with 1 x 104 4T1-Luc cells in 5 µL PBS 
into the brain at a rate of 2.5 µL tumour cells/min using a stereotaxic frame with pre-defined 
coordinates relative to bregma (x=-2 mm, y=1 mm, z=-2 mm). At post-mortem, brains were 
IVIS imaged ex vivo, fixed in 4% paraformaldehyde for 24 h and paraffin embedded. For 
intracardiac inoculation, mice were anaesthetized with isoflurane and 5 x 104 4T1 (BALB/c 
mice) or 3 x 105 MDA-MB-231 cells (NSG mice) were injected into the left ventricle of the heart 
in 100 µL PBS. At the end of the experiment, post-mortem tissues were IVIS imaged ex vivo, 
fixed in 4% paraformaldehyde for 24 h, and either paraffin embedded or frozen. 
For RNA expression analysis of freshly isolated cells, 4T1-Luc-RFP cells were 
inoculated either subcutaneously (5 x 105 cells), intravenously via the lateral tail vein (1 x 105 
cells) or, as described above, intracranially (1 x 104 cells). 9 - 13 days later, primary tumours, 
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lungs and brains were collected. Primary tumours were dissociated using the MACS mouse 
tumour dissociation kit (Miltenyi Biotec), lungs and brain were dissociated using the MACS 
lung dissociation kit. RFP-positive 4T1-Luc cells were FACSorted directly into RLT lysis buffer 
(Qiagen) for RNA extraction. 
 For fluorescent imaging of brain sections, whole 4% paraformaldehyde fixed brains 
were submerged in 30% sucrose in PBS at 4°C before moulding in OCT and freezing in dry 
ice plus isopentane. The frozen brain was cryostat sectioned at 20 µm intervals. For imaging 
mCherry-positive cells, sections were defrosted, washed in PBS, DAPI stained, mounted and 
scanned using Vectra 3.0 automated quantitative pathology imaging system (Perkin Elmer). 
 For histological and immunohistochemical analysis, FFPE brain sections were H&E or 
antibody stained and scanned on the NanoZoomer digital slide scanner (Hamamatsu). 
Tumour burden was quantified using ImageJ in a coronal section taken at median level 
through each brain.  
 
Gene expression profiling 
RNA extracted (RNeasy Mini kit) from independently isolated 4T1 sublines derived from 
primary tumour (T, n=3), brain metastases (B, n=4), and lung metastases (L, n=3) was 
subjected to microarray analysis on Mouse WG-6 v2.0 expression BeadChips (Illumina, San 
Diego, CA, USA). RNA amplification, labelling and hybridization were performed according to 
the manufacturer's instructions at Cambridge Genomic Services. The raw data was extracted 
using GenomeStudio Software and was processed in R using lumi package 
(http://www.bioconductor.org). In brief, data was (i) filtered to remove any non-expressed 
probes (detection p>0.01) across samples involved in a given group comparison, (ii) 
transformed using the variance-stabilising transformation, (iii) normalised using the robust 
spline normalisation method. 
 Sample relations were estimated using unsupervised hierarchical clustering 
(Euclidean distance, average linkage) based on 17550 probes. Two-sample t-tests (with 
random variance model) were used to identify differentially expressed genes between (i) L 
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and T, (ii) B and L, and (iii) B and T sublines, using the BRB-Array Tools 
(https://brb.nci.gov/BRB-ArrayTools) with a threshold of parametric p-value <0.001. When 
multiple probes were mapped to the same gene, the most variable probe measured by 
interquartile range (IQR) across the samples was selected to represent the gene. Gene 
expression data is deposited at GEO with accession number GSE110101. 
 
Real-time quantitative PCR (RT-qPCR) 
RNA from cultured cells or whole mouse tissue, or from freshly isolated tumour cells was 
extracted using the RNeasy Mini kit or the RNeasy Plus Micro kit respectively, according to 
the manufacturer’s instructions. RNA was eluted in 10-30 µL nuclease-free water. The RNA 
concentration was measured in 1 µL sample using Qubit2.0 Fluorometer (Invitrogen) or ND-
1000 Spectrophotometer (Nanodrop). cDNA was produced by reverse transcribing 150-500ng 
of RNA using the QuantiTect reverse transcription kit (Qiagen) or SuperScript IV First-Strand 
Synthesis System (Invitrogen) according to the manufacturer’s instruction. qPCR was 
performed on 11.25 ng cDNA (4.5 µL) with 0.5 µL Taqman Gene Expression Assay probe and 
5 µL 2x qPCR Master mix per well. Relative quantification was performed on QuantStudio 
Real-time PCR software or on ABI Prism 7900HT sequence detection system. Each reaction 
was performed in triplicate. Data was analysed using QuantStudio Real-time PCR or SDS 
2.2.1 software, and relative expression levels were normalised, unless otherwise stated, to 
B2m/B2M or Gapdh endogenous control, with a confidence interval of 95% for all assays.  
 
Spheroid growth assays 7.5 x 102 cells/well were sorted into U-bottom low adherence 96-well 
plates (Corning) in DMEM containing 2% FBS. 7 days post-seeding, the viability of the cells 
in the 3D tumour spheroids was assessed using CellTiter-Glo (Promega) with luminescence 
quantified using a Victor X5 plate reader. 
 
Anoikis assay 5 x 104 cells/well were seeded into low adherence 6-well plates (Costar) in 
DMEM containing 2% FBS. 24 h post seeding, cells were stained with Annexin V-APC/ PI 
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Apoptosis Detection Kit (eBioscience) and analysed using a BD Biosciences LSRII flow 
cytometer with FACSDIVA and FlowJo software. Cell viability was measured as proportion of 
healthy (Annexin negative, PI negative) cells. 
 
Human and mouse datasets  
The expression levels of ID2 and ALDH3A1 and their relation to receptor status of oestrogen 
receptor (ER), progesterone receptor (PR), and HER2 were assessed for breast cancer 
samples in TCGA [10]. Expression level of BMP7 in non-tumour bearing mice was assessed 
in (i) brain astrocytes, neurons and microglia using the Srinivasan et al. RNAseq dataset [11], 
and (ii) brain microglia and astrocytes using the Kamphuis et al. microarray dataset [12]. 
Clinical significance (distant metastasis-free survival, DMFS) of ID2 and ALDH3A1 expression 
in ER- breast cancers was assessed using publicly available data from Gyorffy et al. [13]. 
Associations of ID2 and ALDH3A1 mRNA levels and brain metastasis were tested in four 
breast cancer datasets (GSE2034, GSE2603, GSE12276, and GSE14020), normalized by 
MAS5.0, log2 transformed, and batch corrected. The tumour subtype information was 
published in a previous study [14]. The datasets contained 104 ER- breast cancer patients 
who either had no metastatic relapse (n=71) or brain-only metastatic relapse (n=33). Brain 
metastasis relapse-free survival analysis was performed using the upper tertile of gene 
expression to dichotomise the breast cancers. 
 To assess expression of ID2 in primary breast cancers and breast cancer brain 
metastases, the datasets described in Schulten et al. (GSE100534) [16] and Harrell et al. 
(GSE26338) [15] and were retrieved. GSE26338 contains data deposited from 7 different 
platforms. Samples run on platform GPL5325 were enriched for metaplastic breast cancers 
and therefore excluded. 
 
Statistical analysis 
Statistics were performed using GraphPad Prism 7. Unless stated otherwise, data represent 
mean values ±SEM. Where the groups followed normal distribution and had equal variances 
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the significance of the differences of the groups was tested using either unpaired Student's t-
test (two groups) or one-way ANOVA (multiple groups) followed by Bonferroni post-hoc testing 
for correcting multiple comparisons. If groups did not follow a normal distribution, non-
parametric Mann-Whitney (two groups) or Kruskal-Wallis (multiple groups) tests were used. 
Statistical significance was defined as: *, p<0.05; **, p<0.01; ***, p<0.001. 
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Results 
Increased Id2 and Aldh3a1 expression in breast cancer cells disseminated to the brain 
To establish a model that more closely mimics the clinical scenario, 4T1 mouse mammary 
carcinoma cells were grown as primary tumours in syngeneic BALB/c mice. At the termination 
of the experiment, brains, lungs and primary tumours were individually dissociated to derive 
4T1 sublines isolated from different sites. By this approach, tumour cells were detected in the 
brains of ~25% of the mice, an incidence that is lower than with intracardiac inoculation but 
represents a model in which cells have followed the full metastatic cascade. Unsupervised 
hierarchical clustering of independent 4T1 sublines isolated from primary tumours (n=3), lungs 
(n=3) and brains (n=4) revealed a separation of the brain-derived sublines from the lung and 
primary tumour cultures (Fig. 1a). Similarly, two-sample t-tests of 4T1 sublines (Fig. 1b) 
identified differentially expressed genes (p< 0.001) as follows; 162 genes differentially 
expressed between lung and primary tumour sublines (122 upregulated in L, 40 
downregulated in L), 536 genes differentially expressed between brain and lung sublines (248 
upregulated in B, 288 downregulated in B) and 786 genes differentially expressed between 
brain and primary tumour sublines (379 upregulated in B, 407 downregulated in B). Overall, 
the tests revealed a closer relationship between the primary tumour and lung sublines than 
between the brain sublines and either the tumour or lung sublines. A heat map displaying the 
186 highly significantly expressed genes (absolute fold change ≥2.0, p<0.001) between L and 
T, between B and L or between B and T is provided in Fig. 1c, with a higher power image 
showing all differentially expressed gene names in Additional file 1; Fig. S1. 
 A shortlist of potential enhancers of brain metastasis was generated by identifying 
upregulated genes (absolute fold change ≥2.0, p<0.001) in B versus T and B versus L but not 
between L and T (n=29 genes; Additional file 1; Fig S2). Of these, 5 genes (Aldh3a1, Bdh2, 
Gpnmb, Id2, Uap1l1) were selected for further validation based on a combination of literature 
searching and ingenuity pathways analysis. RT-qPCR was performed using RNA isolated 
from the profiled sublines (B1-B4, L1-L3, T1-T3) plus from 5 or 6 independently isolated brain 
metastasis sublines. Id2 and Aldh3a1 were consistently upregulated in the independent brain-
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derived sublines, compared to both the primary tumour and lung-derived sublines (Fig. 1d). 
Moreover, elevated Id2 and Aldh3a1 protein levels were detected by immunoblotting in the 
original brain-derived sublines (Fig. 1e) as well as in the independent sublines isolated from 
the brains of tumour bearing mice (Fig. 1f).  
 Finally, to confirm that expression Id2 and Aldh3a1 is upregulated in tumour cells 
colonising the brain in vivo, 4T1 tumour cells were freshly isolated from the brains, lungs and 
primary tumours and immediately analysed by RTqPCR. Consistent with our previous findings 
(Fig 1b), both Id2 and Aldh3a1 were significantly upregulated in tumour cells isolated from the 
brain compared to the primary tumour, with a higher expression of these genes in the brain-
derived cells compared to those isolated from the lungs (Fig. 1g).   
 ID2 (inhibitor of differentiation 2 or inhibitor of DNA binding 2) is a helix-loop-helix 
(HLH) containing protein that lacks a DNA binding domain and is one of the 4 members of the 
ID family (ID1 - ID4). Id proteins dimerise with E protein, Pax and Ets transcription factors, 
preventing the formation of DNA-binding transcription complexes [17]. Via their role in 
inhibiting differentiation and promoting 'stemness' and cell proliferation, ID proteins have been 
implicated in tumour progression in a variety of cancers [18]. ALDH3A1 (aldehyde 
dehydrogenase 3A1) belongs to the ALDH superfamily consisting of 19 members. In addition 
to their role in converting both cytotoxic endogenous and exogenous aldehydes to their 
corresponding carboxylic acids in an NAD(P)+- dependent manner [19],  ALDH activity is a 
commonly used marker for identifying cancer cell populations with increase stem or stem-like 
properties [20, 21]. Although the majority of these studies have focussed on ALDH1A1, 
ALDH3A1 has been reported to be upregulated in prostate cancer stem cells and in metastatic 
lesions compared to primary tumours [22] as well as being required for stem cell maintenance 
and resistance to cytotoxic drugs [23, 24]. 
 
Elevated Id2 and Aldh3a1 expression promotes tumour cell colonisation in the brain 
To assess whether Id2 and/or Aldh3a1 play a role in promoting growth of tumour cells in the 
brain, 4T1-Luc cells were transduced with lentiviruses containing non-targeting control shRNA 
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(shNTC) or shRNAs targeting Id2 (shId2) or Aldh3a1 (shAldh3a1) (Fig. 2a) and inoculated 
intracranially into BALB/c mice. Ex vivo IVIS imaging of the brains post-mortem revealed a 
significant reduction in tumour burden in both the shId2 and shAldh3a1 groups (Fig. 2b). This 
finding was confirmed by histological examination of brain sections (Fig. 2c). Although these 
data indicate that Id2 and Aldh3a1 expression is required for efficient tumour growth in the 
brain, they do not address whether these genes play a role in promoting brain colonisation of 
tumour cells from the circulation. Due to the lack of mouse models with which to reproducibly 
monitor spontaneous breast cancer metastasis, we ectopically expressed Id2 or Aldh3a1 in 
mouse 4T1-Luc cells and in the human breast cancer cell line, MDA-MB-231-Luc (Fig. 3a) 
and performed intracardiac inoculation of the manipulated cells into BALB/c and NSG mice, 
respectively. For the 4T1-Luc cells, ectopic expression of Aldh3a1 resulted in a significant 
increase in tumour cell colonisation of the brain as monitored by ex vivo IVIS imaging. 
Increased Id2 expression also increased brain colonisation but this did not reach significance 
(Fig. 3b). However, examination of brain sections revealed that, compared to the control cells, 
cells with either ectopic Id2 or Aldh3a1 expression were better spread into the perivascular 
space of the brain parenchyma (Fig. 3b, right panels). Consistent with the gene expression 
profiling (Fig. 1), ectopic expression of either Id2 or Aldh3a1 had no impact on the level of 
tumour burden in the lung (Fig. 3c, left panel) but significantly increased tumour burden in the 
brain (Fig 3c, middle and right panels). Finally, we examined the distribution of tumour cells in 
the brain by costaining sections with the endothelial markers endomucin and CD31, and an 
antibody against human lamin A/C to detect the MDA-MB-231-Luc cells. As has been 
previously reported [25-28], the majority of tumour cells had extravasated into the brain 
parenchyma and were growing in the perivascular space (Fig. 3d).  
 
Elevated ID2 expression associates with poor outcome in patients with brain metastases 
Next we addressed the clinical relevance of these findings for human breast cancer patients. 
Examination of the TCGA breast cancer dataset revealed higher levels of ID2 and ALDH3A1 
expression in triple negative (ER-, PR-, HER2-) breast cancers compared to HER2+ and 
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ER+/HER2- breast cancers (Fig. 4a), and in ER- versus ER+ breast cancers (Fig. 4b). 
Moreover, in ER- breast cancers elevated expression of either ID2 or ALDH3A1 was 
associated with reduced distant metastasis-free survival (Fig. 4c). More importantly, elevated 
expression of ID2 was associated with reduced brain metastasis free-survival, whereas there 
was no significant association of ALDH3A1 expression levels with outcome in these patients 
(Fig. 4d). Consistent with our mouse experimental studies demonstrating elevated Id2 
expression in cells isolated from brains compared to primary tumours (Fig. 1g), interrogation 
of human datasets containing gene expression profiling of primary breast cancer and breast 
cancer brain metastases revealed a significantly increased level of ID2 expression in the brain 
samples. As a consequence, we focussed the remainder of our studies on ID2.  
 
BMP7 signalling promotes Id2 expression and enhances cell survival 
It has been reported previously that ID2 expression is positively regulated by bone 
morphogenic protein 7 (BMP7) signalling but negatively regulated by TGFβ1 [29, 30]. 
Interestingly, in non-tumour bearing mice, Bmp7 expression is substantially higher in the brain 
than the lungs, whereas expression of Tgfb1 is higher in the lungs compared to the brain (Fig. 
5a). Examination of publicly available datasets revealed a significant enrichment of Bmp7 
expression in brain astrocytes compared to microglia or neurons (Fig. 5b). To directly address 
whether BMP7 can induce Id2 expression in the tumour cells, 4T1-Luc cells were untreated 
or treated for 2 to 24 h with either BMP7 or TGFβ1. BMP7, but not TGFβ1, treatment promoted 
a profound increase in Id2 mRNA levels (Fig. 5c). Moreover, this elevated expression 
persisted for up to 5 days after removal of BMP7. These effects were not restricted to the 
mouse 4T1-Luc cells as equivalent results were obtained with the MDA-MB-231 cells (Fig. 
5e,f). We also investigated the expression of other Id family members, Id1, Id3 and Id4. All 
family members showed elevated expression in the 4T1-Luc sublines isolated from the brains 
of tumour-bearing mice, compared to the lungs or primary tumour sublines (Fig. 5g). In 
addition, expression of Id1 and Id3, and to a lesser extent Id4, was dramatically elevated 
following BMP7, but not TGFβ1, treatment (Fig 5h).  
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 Finally, we determined the mechanism by which Id2 might promote colonisation of the 
brain. Tumour cells disseminating to the brain will find themselves in a foreign environment 
and in particular an environment devoid of many of the extracellular matrix components found 
in primary tumours or in the lungs [31]. To mimic a matrix poor environment, 4T1-Luc cells 
were cultured in low adherence plates. In these conditions either ectopic expression of Id2 
(Fig. 6a) or treatment with BMP7 to induce Id2 expression (Fig. 6b) resulted in a higher 
proportion of non-apoptotic 4T1-Luc cells remaining after 24 hours. To extend these 
observations, 4T1-Luc cells were cultured as 3D tumour spheroids by plating cells into low-
adherence U bottomed plates (Fig. 6c). Treatment with BMP7 of either 4T1-Luc parental cells, 
4T1-Luc cells transduced with empty vector (Vec) or with a non-targeting control shRNA 
(shNTC) resulted in increased viability of cells within the spheroids. Conversely, knockdown 
of Id2 expression (shId2) impaired viability and impaired the ability to respond to BMP7 
treatment. 
 
 
Discussion 
In this study we generated a set of 4T1 sublines derived from primary tumours and from 
tumour cells that had spontaneously disseminated to either the brain or lungs of BALB/c mice. 
By pairwise gene expression profiling we sought to identify differentially expressed transcripts 
specifically associated with metastasis to the brain. Moreover, as these sublines were derived 
in the context of a spontaneous metastasis model where the number of circulating tumour 
cells reaching secondary sites is very limited, we reasoned that differentially expressed genes 
were more likely to be involved in survival of cells in the brain and the early stages of metastatic 
colonisation rather than the expansion of established macrometastatic disease.  
 Two differentially expressed genes were selected for in vivo validation, Aldh3a1 and 
Id2. Downregulation of either gene resulted in reduced tumour burden following intracranial 
inoculation whereas ectopic expression in either mouse or human tumour cells resulted in 
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increased metastatic burden in the brain following intracardiac inoculation but did not promote 
increased metastasis to the lung.  
 Tumour cells colonising the brain face unique challenges. First, the tumour cells have 
to navigate across the blood-brain barrier that separates the brain from the general circulation 
[32]. Second, the cellular and non-cellular composition of the brain is distinct from that found 
both in the primary tumour and at other metastatic sites. For example, tumour cells 
metastasising to the brain have to avoid apoptosis mediated by astrocyte secreted Fas ligand 
[26, 33] and detection and elimination by reactive microglia [6]. Similarly the absence of 
stromal fibroblasts and fibrillar collagen [31] means that infiltrating tumour cells have to adapt 
to the foreign extracellular matrix composition. Finally, successful metastasising cells have to 
adapt to an altered metabolic environment [7, 34]. The brain consumes ~20% of the body’s 
glucose-derived energy but when blood glucose is low, the brain can adapt its metabolism to 
use acetate, ketone bodies or fatty acids as alternative fuels. Metastasising tumours cells need 
to have metabolic flexibility to survive in this environment.  
  As has been reported in other studies [25-28], in the models used here it was observed 
that tumour cells disseminated to the brain parenchyma remain closely located to the brain 
capillaries (see Fig 3). It is now well established that cancer stem cells reside in niche 
microenvironments, including perivascular niches in the brain [35], and that these niches serve 
to maintain the tumour cell 'stemness' [36]. As both ID2 and ALDH3A1 have been implicated 
in promoting stem cell-like features in tumour cells [18, 24, 37], their elevated expression may 
provide an advantage in the early stage of metastatic colonisation by retaining cells in the 
niche until they are ready to face the full challenges of the brain microenvironment. In addition, 
among the ALDH family, ALDH3A1 has a specific role in peroxidic aldehyde metabolism [24, 
38]. In metabolically challenging conditions, particularly in conditions of high oxidative stress, 
production of reactive oxygen species (ROS) leads to peroxidation of lipids, which in turn give 
rise to cytotoxic lipid aldehydes. The ability of ALDH3A1 to function as lipid aldehyde 
scavenger [39] would provide a survival advantage for disseminating tumour cells 
encountering adverse conditions. However, it was notable in this study that when expression 
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of ALDH3A1 was examined in breast cancer clinical datasets, high expression significantly 
associated with an increased risk of distant metastatic relapse but not with brain specific 
relapse (Fig. 4c,d). Consequently, although the models used in this study identified increased 
Aldh3a1 expression to be associated with increased brain but not lung metastasis, the clinical 
data point to a more general pro-metastatic function. By contrast, ID2 expression in clinical 
samples correlated with increased distant metastatic relapse and brain specific metastatic 
relapse. 
 ID proteins are negative regulators of basic HLH (bHLH) transcription factors and, 
additionally, ID2 can bind and override the tumour suppressor function of retinoblastoma (RB) 
tumour suppressor. In normal cells, these activities underpin the role of ID proteins in inhibiting 
cell differentiation and promoting cell proliferation. In cancers, ID proteins are found at a higher 
level than in normal adult tissues where they function to sustain self renewal of stem or stem-
like cancer cells and inhibit apoptosis and entry of tumour cells into senescence [17, 18]. For 
ID2 it has been shown that expression is required to maintain glioma [40], glioblastoma [41], 
head and neck [42] and colorectal cancer stem/stem-like cells. Previously it has been 
demonstrated in normal mouse mammary cells and other non-transformed epithelial cell types 
that exposure to TGFβ resulted in decreased ID2 mRNA and protein levels, whereas the bone 
morphogenic protein BMP7 could both override the TGFβ-mediated ID2 repression and, on 
its own, promote increased ID2 expression [29, 30, 43]. BMPs are members of the TGFβ 
superfamily but whereas TGFβs bind to the TGFβ type 1 receptors  ALK1 and ALK5, BMPs 
bind to BMP-specific ALK receptors, with BMP7 binding to ALK2 [44].  
 Given the role reported here for ID2 in promoting breast cancer metastasis to the brain, 
it was striking that although levels of Tgfb1 mRNA were approximately 2-fold higher in the 
normal mouse lung compared to brain, levels of Bmp7 mRNA were >100-fold higher in brain 
compared to lung. Moreover, whereas treatment with TGFβ1 had little impact on ID2 
expression in either mouse mammary carcinoma or human breast cancer cells, BMP7 
treatment resulted in a >50-fold increase in ID2 mRNA levels and this level of expression was 
sustained for at least 5 days following BMP7 withdrawal. Together with the demonstration that 
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increased Id2 expression protects tumour cells from loss of attachment induced anoikis and 
promotes growth of 3D tumour spheroids, the data presented here supports a model in which 
spontaneously metastasising breast cancers cells with higher ID2 expression will have a 
survival advantage when they disseminate to the brain and that once in the brain, cells that 
are receptive to BMP7 signalling to maintain high level ID2 expression will be better able to 
progress to macrometastatic disease by tolerating the harsh pro-apoptotic brain 
microenvironment.  
 
Conclusions 
The incidence of brain metastasis in breast and other cancers is increasing, yet patient 
prognosis after a diagnosis of metastatic relapse in the brain remains dismal. This situation is 
further compounded by the lack of prospective clinical trial data to assess the efficacy of 
current system therapies in patients with brain metastases [1]. In addition, there is an urgent 
need to develop methodologies for the identification of patients at high risk of developing brain 
metastasis and to better understand the unique biology associated with tumour cell 
colonisation of the brain to identify potential new therapeutic strategies. Using a model that 
more faithfully recapitulates the dissemination of tumour cells to secondary sites, combined 
with in vivo and in silico validation studies, we identified ID2 as a promising brain metastasis 
promoter. Future studies will be required to assess whether monitoring ID2 mRNA or protein 
levels in primary tumours or in plasma samples could provide a prognostic biomarker for 
patients at higher risk of relapse in the brain. Finally, it is well documented that ID family 
proteins play a key role in developmental processes and that expression is downregulated in 
most normal adult tissues but can be re-activated in cancer cells [17, 18]. Although this pattern 
of expression make ID proteins potential therapeutic targets, helix-loop-helix proteins are 
typically described as 'undruggable'. However, in recent years there have been rapid 
technological advances in developing inhibitors of protein-protein interaction as well as 
approaches for targeted protein degradation such as proteolysis targeting chimaeras 
(PROTACs), bifunctional molecules for highjacking E3 ligases or small molecules that redirect 
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E3 ligase activity [45]. The development of reagents that can inhibit ID2 dimerisation or 
promote its degradation will, in the future, allow robust assessment of ID2 as a potential 
therapeutic target to prevent or limit the development of breast cancer brain metastasis.  
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Figure legends  
 
Fig. 1 Gene expression profiling of 4T1 sublines from primary and metastatic sites. 4T1-Luc 
sublines independently isolated from primary tumours (T1 - T3), lungs (L1 - L3) or brains (B1 
- B4) were subject to gene expression profiling. a. Unsupervised hierarchical clustering 
(Euclidean distance, average linkage) estimating the relation of the independent 4T1 sublines 
based on 17550 probes. b. Volcano plots showing differentially expressed genes (p<0.001) 
between L vs. T, B vs. L, and B vs. T. X axis, gene expression shown on Log2(fold-change) scale; 
Y-axes, significance shown on -Log10(p-value) scale. c. Heat map (Pearson, ward.D2) of 186 
genes (with official mouse gene symbol) differentially expressed between B and T, between 
B and L, or between L and T sublines with an absolute fold change ≥2.0, p<0.001. Sublines 
are in the same order as in Fig. 1a. Arrowheads indicate Id2 and Aldh3a1. See Additional file 
1; Fig. S1 for higher power image including gene names. d. RT-qPCR analysis of Id2 and 
Aldh3a1 expression in sublines used in Panel 1a plus 5 or 6 independently isolated brain 
metastasis sublines. e,f. Immunoblotting of (e) sublines used in Panel a or (f) independently 
isolated 4T1-Luc T, L and B sublines. Molecular size makers are in kDa. Arrows indicates the 
lower migrating Aldh3a1 protein. g. 4T1-Luc-RFP cells were isolated from primary tumours, 
lungs and brains of BALB/c mice inoculated subcutaneously, intravenously or intracranially, 
respectively. Expression of Id2 and Aldh3a1 was analysed by RT-qPCR, n=5 mice per group 
±SEM.  ns, not significant, (**), p<0.01; (***), p<0.001, one-way ANOVA. 
 
Fig. 2 Downregulation of Id2 or Aldh3a1 expression impairs tumour growth in the brain. a. RT-
qPCR analysis of Id2 (left panel) and Aldh3a1 expression in 4T1-Luc cells transduced with 
lentiviral non-targeting control (shNTC) shRNA or shRNAs targeting Id2 (shId2) or Aldh3a1 
(shAldh3a1), n=3. b. 1 x 104 4T1-Luc cells were inoculated intracranially into BALB/c mice, 
n=4-6 mice per group ±SEM. (**), p<0.01; (*), p<0.05, Kruskal-Wallis test. At day 9 whole 
brains were collected at necropsy and subjected to ex vivo IVIS imaging (left panel), IVIS 
images are shown (right panel). (c) Brains from panel b were fixed, paraffin embedded and 
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sectioned for histological (H&E) quantification of tumour burden (left panel), ±SEM, (*), p<0.05; 
Kruskal-Wallis test. Right panel, representative histological sections. Scale bar, 2.5 mm.  
  
Fig. 3 Increased Id2 or Aldh3a1 expression enhances metastatic colonisation of the brain 
following intracardiac inoculation. a. 4T1-Luc or MDA-MB-231 cells with ectopic expression of 
Id2 or Aldh3a1 or transduced with mCherry vector (Vec) alone. Left panels, RT-qPCR analysis 
of Id2 and Aldh3a1 expression. Right panel, Id2 and Aldh3a1 protein levels assessed by 
immunoblotting. b. BALB/c mice inoculated via the left ventricle with 5 x 104 4T1-Luc cells, 
n=7 or 8 mice per group. At day 9, whole brains were collected at necropsy and subject to ex 
vivo IVIS imaging ±SEM; (*), p<0.05; ns, not significant; Kruskal-Wallis test. Right panel, 
representative images of mCherry fluorescent tumour cells in brain sections. Scale bar, 100 
µm. c. 3 x 105 MDA-MB-231-Luc cells were inoculated into left ventricle of NSG mice, n=9 to 
10 mice per group and the experiment terminated on day 23 organs subject to ex vivo IVIS 
imaging. Shown are quantification of ex vivo IVIS signals in the lungs (p=ns) and brains; (*), 
p<0.05): (**), p<0.01); Kruskal-Wallis test. Right panel, representative IVIS images of brains. 
d. Sections of fixed and paraffin embedded brains from Panel c were co-stained for endothelial 
cell markers endomucin and CD31 (both in blue) and the human nuclear envelope marker 
lamin A/C (brown). Scale bar, 100 µm. Arrowheads indicate endomucin/CD31 stained 
vasculature.  
 
Fig. 4 Elevated ID2 expression correlates with poor patient outcome. a,b. Tukey plots 
representing the expression of ID2 and ALDH3A1 in the TCGA datasets based on receptor 
status. Box indicates the 1st and 3rd quartiles, bar indicates median, whiskers indicated 1.5 
IQR (interquartile range), and dots indicate outliers. Number of samples is shown in 
parentheses. a.  Adjusted p-values determined using one-way ANOVA followed by Tukey’s 
multiple comparisons test. (**), p<0.01; (*), p<0.05; ns, not significant. b. p-values determined 
using Mann-Whitney test (p<0.0016 for ID2, p<0.0028 for ALDH3A1). c. Kaplan-Meier 
analysis of breast cancer-specific distance metastasis free survival (DMFS) in the 218 ER-
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negative tumours of the Gyorffy et al. dataset [13]. Number of samples in each group, hazard 
ratios (HR) and log rank Mantel-Cox p-values are shown. d. Kaplan-Meier analysis of brain 
metastasis relapse free survival (RFS) in the cohort of 104 ER-negative tumours from patients 
who had either no metastatic relapse or brain-only relapse (see Methods). Hazard ratios (HR) 
and log rank Mantel-Cox p-values are shown. e. Comparison of ID2 expression in primary 
breast cancers and breast cancer brain metastases in the Schulten et al. [16] (left panel) and 
Harrell et al. [15] (right panel) datasets. Number of samples is shown in parentheses. Data 
represent normalised expression values ±SEM. 
 
Fig. 5 Id2 expression is induced by BMP7 but not TGFβ1. a. RT-qPCR analysis of Bmp7 and 
Tgfb1 expression in brains and lungs from naïve BALB/c mice (n=3 independent samples), 
(***), p<0.001; (*) p<0.05; Student’s t-test. b. Expression levels of Bmp7 in mice cells types 
isolated from non-tumour bearing mice in the Srinivasan RNAseq dataset [11], GSE75246; 
n=4 or 5 samples per cell type) and Kamphuis dataset [12], GSE74614); n=12 samples per 
cell type). Scatter plots represent median; (*), p<0.05; (***), p<0.001; Mann Whitney test. c. 
RT-qPCR analysis of Id2 expression in 4T1-Luc cells treated with recombinant TGFβ1 (5 
ng/mL) or BMP7 (300 ng/mL) for 2 - 24 hours. Data represents 2 wells/condition ±SEM and is 
shown relative to the untreated sample (***), p<0.001; one-way ANOVA. d. 4T1-Luc cells were 
treated with BMP7 (300 ng/mL) for 24 hours, cells were washed and incubated in complete 
media for a further 1 or 5 days before Id2 expression was assessed by RT-qPCR. Data 
represents 2 wells/condition ±SEM. (**), p<0.01; Student’s t-test. e,f. ID2 expression levels in 
MDA-MB-231-Luc cells treated as described in Panels b and c; ns, not significant; (*), p<0.05; 
one-way ANOVA and Student’s t-test. g. RT-qPCR analysis of Id1, Id3 and Id4 expression in 
4T1-Luc tumour sublines independently isolated from primary tumours, lungs and brains, 
relative to Gapdh. p-values generated using Mann-Whitney test between tumour and brain; 
(*), p<0.05; (**), p<0.01 (lungs were not included in statistical analysis as n=2 samples). h. 
RT-qPCR analysis of Id1, Id3 and Id4 expression levels in 4T1-Luc cells treated with TGFβ1 
(5 ng/mL) or BMP7 (300 ng/mL) for 2 - 24 hours. Data represents 2 samples per time point, 
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±SEM and is shown relative to untreated samples. (*), p<0.05; (**), p<0.01; (***), p<0.001; ns, 
not significant; one-way ANOVA.  
 
Fig. 6 Id2 expression protects against apoptosis. a. 5 x 104 4T1-Luc cells expressing vector 
alone (Vec) or with ectopic expression of Id2 were cultured in 6-well low adherence plates in 
2% FBS for 24 hours before annexin V, PI staining. Data shown is % of healthy cells (annexin 
V-, PI-) remaining, n=3 ±SEM; (**), p<0.01; Student’s t-test. b. Parental 4T1-Luc cells cultured 
in suspension as described in panel a in the presence of absence of BMP7 (300 ng/mL) for 
24 hours prior to annexin V, PI staining. Data shows % of healthy cells (annexin V-, PI-) 
remaining, 3 samples per condition ±SEM; (**), p<0.01; Student’s t-test. c. 750 parental 4T1-
Luc cells (4T1) or 4T1-Luc cells transduced with empty vector (Vec) or with ectopic expression 
of Id2, or 4T1-Luc cells transduced with non-targeting control shRNA (shNTC) or shRNA 
targeting Id2 (shId2) were sorted into low adherence 96-well U-bottomed plates in DMEM plus 
2% FBS and cultured in the presence or absence of BMP7 (300 ng/mL) for 7 days before 
viability was monitored by CellTiter-Glo. Data from n=5 wells sample, ns, not significant, (*) 
p<0.05; (**), p<0.01; (***), p<0.001; two-way ANOVA with Tukey's post-test. 
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Table S1 MISSION shRNA pLKO-puro transduction particles 
Clone I.D. Gene targeted Species targeted Named 
SHC202V None None shNTC 
TRCN0000054390 Id2 Mm shId2 
TRCN0000042078 Aldh3a1 Mm shAldh3a1 
 
 
 
 
 
 
Table S2 ORF clone expression systems 
Vector I.D. Tag Species Gene Named 
pReceiver-
LV166 N/A 
IRES2-
mcherry N/A  Vec 
pReceiver-
LV166 Mm03201 
IRES2-
mcherry Mouse 
Id2 
(NM_010496.3) 
Id2 OE 
pReceiver-
LV166 Mm28326 
IRES2-
mcherry Mouse 
Aldh3a1 
(NM_001112725.1) 
Aldh3a1 
OE 
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Table S3 Taqman RT-qPCR gene expression assays 
Gene symbol Gene name Probe set I.D. Species 
B2m β-2 microglobulin Mm00437762_m1 Mm 
B2M β-2 microglobulin Hs99999907_m1 Hs 
Gapdh 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
4352339E Mm 
Id2 inhibitor of DNA binding 2 Mm00711781_m1 Mm 
ID2 inhibitor of DNA binding 2 Hs04187239_m1 Hs 
Aldh3a1 
aldehyde 
dehydrogenase 3 
family member A1 
Mm00839312_m1 Mm 
ALDH3A1 
aldehyde 
dehydrogenase 3 
family member A1 
Hs00964880_m1 Hs 
Id1 Inhibitor of DNA binding 1 Mm00775963_g1 Mm 
Id3 Inhibitor of DNA binding 3 Mm00492575_m1 Mm 
Id4 Inhibitor of DNA binding 4 Mm00499701_m1 Mm 
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Table S4 Antibodies for immunoblotting (IB) and Immunohistochemistry (IHC) 
Antibody target Host Supplier Dilution Application 
Vinculin Mouse Cell signalling 1:1000 IB 
Id2 Mouse 
D39E8 
Cell Signalling 
1:1000 IB 
Aldh3a1 Goat 
ARG65260 
arigobio 
1:10,000 IB 
Lamin A/C Rabbit 
Santa Cruz 
Biotech 
(sc-2004) 
1:500 IHC 
CD31 Rat Dianova (DIA310) 1:75 IHC 
Endomucin  Rat 
Santa Cruz 
Biotech 
(V.7C7; sc-
65495) 
1:1000 IHC 
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SFig. 1 Higher power image of Fig. 1c. Heat map (Pearson, ward.D2) of 186 genes (with 
official mouse gene symbol) differentially expressed between B and T, between B and L, or 
between L and T sublines with an absolute fold change ≥2.0, p<0.001. Sublines are in the 
same order as in Fig. 1a. Arrowheads indicate Id2 and Aldh3a1. 
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SFig. 2. Heat map of shortlisted genes. Heat map (Pearson, ward.D2) of 29 genes (with official 
mouse gene symbol) with upregulated expression (absolute fold change ≥2.0, p<0.001) in B 
versus T and B versus L but not between L and T. Genes further validated by RT-qPCR are 
shown in red.  
 
